The fast-paced life has brought in a series of problems with it. Many diseases which were rare or unheard of previously are pretty common these days. Cancer is one such disease that has seen tremendous growth in the last decade. Apart from environmental and heredity causes, most of them are sporadic. GenepoweRx, Hyderabad-based health tech in the field of biotechnology, has launched a product – OncoRx. Compared to traditional molecular testing, the product helps predict accurate response or resistance to targeted therapies for cancer patients. The critical point is that every cancer is unique, and so is the individual’s body’s response to its treatment.
Scientifically, cancer is a disease that results in the abnormal growth of body cells due to multiple reasons like wrong lifestyle and radiation exposure, but it is often a result of genetic abnormalities. Due to research, scientists are closer to understanding the biology of cancer. Researchers worldwide are developing new treatments and medicines to increase the chances of survival, control the disease and lessen the side effects.
Recently a breakthrough technology Next Generation Sequencing has created ripples in the medical world. NSG helps in understanding multiple pathways resulting in the development of precision medicine. It has led to improving the speed and accuracy while reducing the cost of sequencing. Precision medicine ensures designing a personalized cancer treatment based on an individual’s genes. This ensures a better response to the medication, and chances of survival increase tremendously.
GenepoweRx has partnered with MSK’s Precision Oncology Knowledge Base, the only FDA-recognized database for 127 cancer types and 108 FDA-approved drugs. Memorial Sloan Kettering Cancer Center is the world’s oldest and largest private cancer center. GenepoweRx (by K&H) will utilize MSK’s clinical and research insights into gene mutations associated with solid tumors. The data will be clubbed along with K&H’s proprietary database to provide accurate recommendations for the Indian population.
Dr. Kalyan, founder GenepoweRx shares, “There is a rise in cancer cases, a condition not so common three decades ago, especially among youngsters. There might be environmental and hereditary reasons behind the rise, but most sporadic cases. Targeted therapies will be a first or second option for chemotherapy. More sequencing of tumor cells is needed. It is necessary for the researchers, scientists, and oncologists to collaborate and create a database relevant to India.”
GenepoweRx has launched OncoRx for cancer treatment and developed bioinformatics algorithms for data analysis. This product uses targeted genomic sequencing and analysis and provides crucial information to the physicians about druggable mutations in the patients, where targeted therapies are beneficial. They use Next-generation sequencing, and the health tech uses artificial intelligence and machine learning to make informed decisions.
GenepoweRx is the only company led by physicians in India in the Genomics space. The founders firmly believe that opening a discussion channel between oncologists, pathologists, and genomic specialist physicians will lead to the best treatment choices for the patient.
Follow – https://healthhuff.com for More Updates
Discussion about this post